Literature DB >> 24883334

Influenza Virus H1N1 inhibition by serine protease inhibitor (serpin) antithrombin III.

Donald F Smee1, Brett L Hurst1, Craig W Day1, Ralf Geiben-Lynn2.   

Abstract

Endogenous serine protease inhibitors (serpins) are anti-inflammatory mediators with multiple biologic functions. Serpins are also part of the early innate immune response to viral infection that includes mannose binding lectins, soluble CD14, defensins and antimicrobial peptides. Recently, serpin antithrombin III (ATIII) was shown to have broad-spectrum antiviral activity against HIV, HSV and HCV. We tested ATIII's antiviral activity against a variety of influenza virus strains. In our studies we found strong in vitro inhibition of influenza virus A H1N1 isolates. Our data also demonstrate that ATIII potency was more than 100-fold that of ribavirin. We also found that inhibition was dependent on viral hemagglutinin with decreasing efficacy in the order of H1N1 > H3N2 > H5N1 >> Flu B. In vivo efficacy is currently still lacking demonstrating need for more advanced delivery methods for this biomolecule. Understanding how ATIII regulates influenza virus inhibition may reveal new avenues for therapeutic interventions.

Entities:  

Keywords:  Antithrombin III; Serpin; hemagglutinin dependent; influenza virus H1N1

Year:  2014        PMID: 24883334      PMCID: PMC4037146     

Source DB:  PubMed          Journal:  Int Trends Immun


  25 in total

1.  In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

Authors:  Yohichi Kumaki; Craig W Day; Donald F Smee; John D Morrey; Dale L Barnard
Journal:  Antiviral Res       Date:  2011-09-08       Impact factor: 5.970

2.  Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities.

Authors:  D F Smee; J H Huffman; A C Morrison; D L Barnard; R W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  Lessons from the past: familial aggregation analysis of fatal pandemic influenza (Spanish flu) in Iceland in 1918.

Authors:  Magnús Gottfredsson; Bjarni V Halldórsson; Stefán Jónsson; Már Kristjánsson; Kristleifur Kristjánsson; Karl G Kristinsson; Arthur Löve; Thorsteinn Blöndal; Cécile Viboud; Sverrir Thorvaldsson; Agnar Helgason; Jeffrey R Gulcher; Kári Stefánsson; Ingileif Jónsdóttir
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-23       Impact factor: 11.205

4.  The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1.

Authors:  Luis Fernando Congote
Journal:  Biochem Biophys Res Commun       Date:  2006-03-15       Impact factor: 3.575

5.  Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor.

Authors:  Ralf Geiben-Lynn; Nancy Brown; Bruce D Walker; Andrew D Luster
Journal:  J Biol Chem       Date:  2002-08-20       Impact factor: 5.157

6.  Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses.

Authors:  John C Kash; Kathie-Anne Walters; A Sally Davis; Aline Sandouk; Louis M Schwartzman; Brett W Jagger; Daniel S Chertow; Qi Li; Rolf E Kuestner; Adrian Ozinsky; Jeffery K Taubenberger
Journal:  mBio       Date:  2011-09-20       Impact factor: 7.867

Review 7.  Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus.

Authors:  Ann H Reid; Jeffery K Taubenberger; Thomas G Fanning
Journal:  Nat Rev Microbiol       Date:  2004-11       Impact factor: 60.633

8.  In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes.

Authors:  Mohammed Asmal; James B Whitney; Corinne Luedemann; Angela Carville; Robert Steen; Norman L Letvin; Ralf Geiben-Lynn
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

9.  Inhibition of HCV by the serpin antithrombin III.

Authors:  Mohammed Asmal; Michael Seaman; Wenyu Lin; Raymond T Chung; Norman L Letvin; Ralf Geiben-Lynn
Journal:  Virol J       Date:  2012-10-02       Impact factor: 4.099

10.  Distinct gene loci control the host response to influenza H1N1 virus infection in a time-dependent manner.

Authors:  Tatiana Nedelko; Heike Kollmus; Frank Klawonn; Sabine Spijker; Lu Lu; Manuela Heßman; Rudi Alberts; Robert W Williams; Klaus Schughart
Journal:  BMC Genomics       Date:  2012-08-20       Impact factor: 3.969

View more
  5 in total

Review 1.  Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants.

Authors:  Megan Meyer; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-17       Impact factor: 5.464

Review 2.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

3.  A Novel Neuraminidase-Dependent Hemagglutinin Cleavage Mechanism Enables the Systemic Spread of an H7N6 Avian Influenza Virus.

Authors:  Hyeok-Il Kwon; Young-Il Kim; Su-Jin Park; Eun-Ha Kim; Semi Kim; Young-Jae Si; Min-Suk Song; Philippe Noriel Q Pascua; Elena A Govorkova; Robert G Webster; Richard J Webby; Young Ki Choi
Journal:  mBio       Date:  2019-11-05       Impact factor: 7.867

Review 4.  Antithrombin and Its Role in Host Defense and Inflammation.

Authors:  Christine Schlömmer; Anna Brandtner; Mirjam Bachler
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

Review 5.  Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia.

Authors:  Yan Yang; Hong Tang
Journal:  Cell Mol Immunol       Date:  2016-04-04       Impact factor: 11.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.